Genomic Health's (GHDX) Oncotype DX(R) Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients
More News related to GHDX
- Genomic Health to Present at Piper Jaffray Health Care Conference
- Genomic Health (GHDX) Tops Q3 EPS by 7c
- Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Genomic Health to Announce Third Quarter 2009 Financial Results and Host Conference Call on Wednesday, November 4, 2009
More News related to Corporate News
- NiSource (NI) Comments on Moody's Affirmation of NiSource's Credit Rating
- VocalTec Com (VOCL) Selected by Teledata ICT to Deliver Advanced Hosted PBX Services with Essentra BAX App Server
- Ener1 (HEV) Subsidiary to Supply U.S. DoE Smart Grid With Lithium-Ion Batteries
- Con Ed (ED) to Receive Additional $45M from U.S. DoE Smart Grid Stimulus Program
- RADA Electronic (RADA) Enters $2.6M Contract With Lockheed Martin
Genomic Health, Inc. (Nasdaq: GHDX) announced positive results from the landmark QUASAR validation study, which demonstrated that the Oncotype DX(R) colon cancer test can independently predict individual recurrence risk in stage II colon cancer patients following surgery. Importantly, the Oncotype DX colon cancer Recurrence Score(R) provided additional independent clinical value beyond standard measures. The study showed that the colon cancer Recurrence Score maintained significance (p=0.008), independent of mismatch repair (MMR), also known as MSI (Microsatellite Instability), T-stage, nodes examined, grade and lymphovascular invasion.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
